Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-086415
Filing Date
2024-10-09
Accepted
2024-10-09 09:13:25
Documents
3
Period of Report
2024-10-09

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0217150-6k_neurosense.htm 6-K 11656
2 PRESS RELEASE, DATED OCTOBER 9, 2024, ENTITLED "NEUROSENSE THERAPEUTICS PLANS TO ea021715001ex99-1_neurosense.htm EX-99.1 17243
3 GRAPHIC ex99-1_001.jpg GRAPHIC 27924
  Complete submission text file 0001213900-24-086415.txt   68574
Mailing Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562
Business Address 11 HAMENOFIM ST. BUILDING B HERZLIYA L3 4672562 972-9-9531142
NeuroSense Therapeutics Ltd. (Filer) CIK: 0001875091 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41084 | Film No.: 241361627
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)